article thumbnail

Tofersen

New Drug Approvals

It is administered as an intrathecal injection. [3] 3] The most common side effects include fatigue, arthralgia (joint pain), increased cerebrospinal (brain and spinal cord) fluid white blood cells, and myalgia (muscle pain). [3] 4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] 3 November 2006.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer.

FDA 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

Once bound to HER3-expressing tumor cells, the ADC is designed to be internalized and the cytotoxic payload released to induce DNA damage and cell death. This suggests that bispecific targeting of EGFR and HER3 would bias drug delivery to the brightly expressing cancer cells, with limited normal tissue toxicity.

article thumbnail

k kh,h,,h, jjgm gmm

Twist Bioscience

Learn More > Variant Libraries Order Now TCR Libraries New Combinatorial Variant Library Spread Out Low Diversity Libraries Site Saturation Libraries Enzyme Screening Kits New Watch how Twist builds variant libraries for your perfect application Synthetic Controls Order Now Liquid Biopsy cfDNA Pan-Cancer Reference Standards v2 New Infectious Disease (..)

RNA 52
article thumbnail

Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies

Drug Discovery Today

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 100
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40
article thumbnail

Radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

The Pharma Data

Targeted radioligand therapy is a type of precision medicine combining two key elements: a targeting compound, or ligand, and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. We believe this technology has the potential to transform many patients’ lives.”.